AVDL vs BHC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AVDL Captures Institutional Edge (2โ2 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avadel Pharmaceuticals plc Ordinary Share (AVDL) driven by superior Growth & Margin, Momentum & Technical while BHC counters with relative strength in Valuation, Options & Structure. Fundamentally, AVDL trades at 28.8x Forward P/E with 2.5% operating margin (+54.9% YoY revenue) versus BHC at 1.9x Forward P/E and 27.2% operating margin (+9.7% YoY). In options structure, AVDL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against BHC sits in BREAKOUT (100th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AVDL | BHC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.1B | $3.2B | Larger Scale | BHC |
| Trailing P/E Ratio Valuation | 16.8x | 2.0x | Lower Multiple | BHC |
| Forward P/E Ratio Valuation | 28.8x | 1.9x | Lower Multiple | BHC |
| Revenue Growth (YoY) Growth | +54.9% | +9.7% | Higher Growth | AVDL |
| Operating Margin (TTM) Profitability | 2.5% | 27.2% | Higher Margin | BHC |
| Net Profit Margin Profitability | -0.1% | -7.6% | Higher Margin | AVDL |
| Return on Equity (ROE) Capital Efficiency | -0.3% | -11040.0% | Higher ROE | AVDL |
| 52-Week Range Position Momentum | 89% ($6โ$24) | 83% ($4โ$9) | Stronger Trend | AVDL |
| Beta / 30D Volatility Risk Regime | 0.14ฮฒ ยท 2% Vol | 0.96ฮฒ ยท 111% Vol | Lower Realized Risk | AVDL |
| Unified Institutional Score Composite Signal | 62.9 / 100 (BUY) | 44.1 / 100 (HOLD) | Higher Composite | AVDL |